TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
Phase 3positiveTECVAYLITALVEYPositive
AI Analysis
Summary
Johnson & Johnson announced positive Phase 3 results from the MonumenTAL-6 trial showing TECVAYLI combined with TALVEY reduced disease progression/death risk by 89% and death risk by 62% in relapsed/refractory multiple myeloma. This is the fifth positive Phase 3 study of J&J's multiple myeloma T-cell therapy portfolio in the second-line setting.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Reduced risk of disease progression or death by 89% and risk of death by 62% in relapsed/refractory multiple myeloma
Importance:8/10
Sentiment:
0.90
Phase 3 datamultiple myelomadual antigen targetingBCMAGPRC5DT-cell therapy
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 23, 2026 12:30 PM